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Abstract
Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer
(LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors inﬂuencing conversion to surgical resectability for
LAPC.
Sixty-four patients with LAPC who received FOLFIRINOX as initial chemotherapy were enrolled retrospectively. Demographic
characteristics, tumor status, interval/dosage/cumulative relative dose intensity (cRDI) of FOLFIRINOX, conversion to resection, and
clinical outcomes were reviewed and factors associated with conversion to resectability after FOLFIRINOX were analyzed.
After administration of FOLFIRINOX (median 9 cycles, 70% of cRDI), the median patient overall survival (OS) was 17.0 months.
Fifteen of 64 patients underwent surgery and R0 resection was achieved in 11 patients. During amedian follow-up time of 9.4months
after resection, cumulative recurrence rate was 28.5% at 18 months after resection. The estimated median OS was signiﬁcantly
longer for the resected group (>40 months vs 13 months). There were no statistical differences between the resected and non-
resected groups in terms of baseline characteristics, tumor status and hematologic adverse effects. The patients who received
standard dose of FOLFIRINOX had higher probability of subsequent resection compared with patients who received reduced dose,
although cRDIs did not differ between groups.
FOLFIRINOX is an active regimen in patients with LAPC, given acceptable resection rates and promising R0 resection rates.
Additionally, our data demonstrate it is advantageous for obtaining resectability to administer FOLFIRINOX without dose reduction.
Abbreviations: BMI = body mass index, CECT = contrast-enhanced CT, CIs = conﬁdence intervals, cRDI = cumulative relative
dose intensity, ECOG PS = eastern cooperative oncology group performance status, G-CSF = granulocyte-colony stimulating
factor, LAPC = locally advanced pancreatic cancer, MRI = magnetic resonance imaging, OS = overall survival, PDA = pancreatic
ductal adenocarcinoma, PVT = planning target volume, RECIST = response evaluation criteria in solid tumors, SBRT = stereotactic
body radiotherapy.
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Pancreatic ductal adenocarcinoma (PDA) is associated with a
dismal prognosis, with a 5-year survival rate of 6%.[1] This
disease is one of the leading causes of cancer-related mortality
worldwide, and surgical resection is the only modality that can
lead to long-term survival.[2] However, approximately 80% ofEditor: Jimmy T. Eﬁrd.
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1patients are not surgical candidates, due to distant metastases or
vascular invasion at the time of diagnosis.[2] About 1/3rd of
patients with pancreatic cancers display unresectable localized
disease, and the median overall survival (OS) is approximately 9
to 12 months for this cohort.[3,4]
In the past, most patients with locally advanced pancreatic
cancer (LAPC) could not undergo resection, even after
chemotherapy and chemoradiotherapy, due to lack of effective
chemotherapeutic regimens and local control modalities. As a
result, LAPC was primarily treated with palliation without
curative intent. Since it was discovered that FOLFIRINOX
(ﬂuorouracil, leucovorin, irinotecan, and oxaliplatin) was an
active regimen that improved survival in patients with metastatic
pancreatic cancer up to 11.1 months, there have been several
attempts to use FOLFIRINOX as neoadjuvant chemotherapy for
LAPC.[5–9] A recent meta-analysis of 13 studies found that
FOLFIRINOX could give a quarter of patients with LAPC a
chance to undergo subsequent resection and provide a
substantially longer median survival time of 24.2 months.[10]
However, it remains unclear which factors determine resectabili-
ty after FOLFIRINOX administration in patients with LAPC.
In this study, we report our institutional investigation of
patients with LAPC who were treated with FOLFIRINOX and
assess factors that inﬂuence conversion to resectability with
neoadjuvant FOLFIRINOX in LAPC.
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2.1. Patient and data sources
This is a retrospective study of patients with LAPC who were
treated with neoadjuvant FOLFIRINOX at Seoul National
University BundangHospital between April 2012 and June 2016.
This study was undertaken with the approval of the Institutional
Review Board. We reviewed patient electronic medical records
and subsequently followed their respective clinical courses.
Patients with LAPC who received FOLFIRINOX as 1st-line
treatment were included. They were all diagnosed with PDA by
histology or cytology. The decision of resectability was made
through careful multi-disciplinary pancreatic cancer board
review using pancreatic protocol CT, endoscopic ultrasound,
magnetic resonance imaging (MRI), and PET-CT based on the
National Comprehensive Cancer Network guidelines.
FOLFIRINOX doses were planned according to the protocol
used in the ACCORD11/PRODIGE4 trial.[5] FOLFIRINOX was
administered in 14-day cycles. Oxaliplatin was given at a dose of
85mg/m2 over 2hours, leucovorin at 400mg/m2 over 2hours,
irinotecan at 180mg/m2 over 90 minutes, and 5-FU as a bolus of
400mg/m2. After that, 5-FU was continuously administered with
2400mg/m2 over 46hours. Use of granulocyte-colony stimulat-
ing factor (G-CSF) and dose adjustments were decided at the
discretion of the treating physician, based on development and
severity of neutropenia.
FOLFIRINOX administration proceeded until disease pro-
gression was recognized, surgical resection was achieved, or
unacceptable adverse effects were encountered. The evaluation of
response to FOLFIRINOXwas conducted every 8 to 12 weeks by
contrast-enhanced CT (CECT). When additional assessment was
needed, MRI or PET-CT was used. Whenever response is
evaluated using CECT, resectability was re-evaluated through a
multi-disciplinary pancreatic cancer board review. The patients
who did not obtain resectability, despite adequate administration
of FOLFIRINOX, received stereotactic body radiotherapy
(SBRT). The SBRT was delivered in 5 fractions to a total dose
of 33Gy over 10 days. The target goal for the planning target
volume (PTV) was that ≥ 90% of PTV receives 100% of the
prescription dose (33Gy) and no more than 1mL inside PTV
exceeds 130% of the prescribed dose. All patients received
volumetric modulated arc therapy on the TrueBeam system
(Varian Medical Systems, Inc, Palo Alto, CA).
We analyzed probable related factors to determine subsequent
resectability, such as sex, age, eastern cooperative oncology
group performance status (ECOG PS), body mass index (BMI),
abdominal muscle area (cm2), initial CA19-9 level, location and
size of tumors, and involved vessels. The abdominal muscle area,
composed of paraspinal and abdominal wall muscles at the 3rd
lumbar level, was measured using the SliceOmatic program
(Tomovision, Canada).
We also analyzed chemotherapy cycles, duration, dosage
reduction, cumulative relative dose intensity (cRDI) of FOLFIR-
INOX, and tumor response. The cRDI is the percentage of the
administered cumulative dose to the standard cumulative dose in
a certain period. If FOLFIRINOX is administered regularly on
time for 2 weeks without dose reduction, cRDI is 100%. We
calculated cRDI using a java program that was developed by our
group (http://www.hwang-lab.com/02_rdicalc).[11] The response
evaluation criteria in Solid Tumors 1.1 (RECIST 1.1) guideline
was used for evaluation of the response to the chemotherapy.
Evaluation of FOLFIRINOX toxicity was performed using the
National Cancer Institute Common Toxicity Criteria. R02resection was deﬁned as tumor margins being free of tumor.
The OS was designated as date of diagnosis to the date of death.2.2. Statistical methods
Baseline and demographic characteristics were summarized as
median and range for continuous variables and as frequencies for
categorical variables. Comparisons were performed with the
Mann–WhitneyU [for continuous variables] and Fisher exact test
or Chi-square test [for categorical variables]. A multivariate
logistic regression model was performed to assess predictors
associated with resectability. We consider P value< .05 to
indicate statistical signiﬁcance. The OS was calculated using the
Kaplan–Meier method with corresponding 2-sided 95% conﬁ-
dence intervals (CIs). Statistical analyses were performed using
STATA version 14.0 (Stata Corp, College Station, TX).
3. Results
3.1. Baseline patients’ characteristics
Between April 2012 and June 2016, a total of 64 patients with
LAPC were treated with FOLFIRINOX at our hospital. Clinical
follow-up was accrued through June 2017.
Baseline characteristics are summarized in Table 1. Among 64
patients, 15 patients (23.4%) underwent resection after FOL-
FIRINOX therapy (resected group) and the remaining 49 patients
were categorized in the non-resected group.
The median patient age was 63 years (30–77 years), and
54.7% of patients were male. All patients had an ECOG PS of 0
or 1, and 19 patients (29.7%) required biliary decompression
with bypass procedures such as endoscopic retrograde cholangi-
ography and percutaneous transhepatic biliary drainage to
relieve biliary obstruction at the start of FOLFIRINOX.
Pancreatic cancer was located at head and neck in 42 patients
(65.6%), and the median tumor size was 40mm (range, 16–88
mm). There were no signiﬁcant differences with regard to sex,
age, ECOG PS, BMI, abdominal muscle area, tumor markers,
tumor location, tumor size, and major vessel involvement
between resected and non-resected groups (P> .05) (Table 1).
3.2. FOLFIRINOX treatment and outcomes
Figure 1 provides a ﬂowchart of patient response to therapy. A
total of 556 cycles of FOLFIRINOX were administered to 64
patients (median 9 cycles [1–20]), and the median duration of
FOLFIRINOX was 6.0 months (0.4–12.2 months). The number
of cycles or duration of FOLFIRINOX was not signiﬁcantly
different between the groups (P> .05, Table 2).
Forty patients (62.5%) required dose reductions. Fewer
patients required dose reduction in the resected group than in
the non-resected group (33.3% (5/15) vs 71.4% (35/49),
respectively, P= .013), although cRDIs did not differ between
groups (71.8% vs 69.6%, respectively). Nineteen patients were
not suited for resection and required further SBRT, and resection
was achieved in 2 additional patients after SBRT (Table 2). The
overall response and disease control rates were much higher in
the resected group than in the non-resected group (32.7% and
8.2% vs. 100% and 66.7%, P< .001, respectively) (Table 3).
Adverse effects are summarized in Table 4. There were no
statistical differences between the resected and non-resected
groups in terms of adverse effects, although the non-resected
group showed a higher rate of non-hematologic adverse effects.
Ten out of 64 patients (15.6%) experienced febrile neutropenia,
Table 1
Patients’ baseline characteristics, n=64.
Total patients, n=64 Resection, n=15 Non-resection, n=49 P
Sex, no (%) .242
Male 35 (54.7%) 6 (40.0%) 29 (59.2%)
Female 29 (45.3%) 9 (60.0%) 20 (40.8%)
Median age (range) 63 (30–77) 61 (30–73) 63 (47–77) .236
ECOG PS
∗
.567
0 30 (46.9%) 8 (53.3%) 22 (44.9%)
1 34 (53.1%) 7 (46.7%) 27 (55.1%)
BMI† (range) 22.0 (15.5–29.8) 23.0 (18.9–29.8) 21.0 (15.5–27.8) .076
Muscle area (cm2) 110.9 (104.7–117.1) 107.7 (94.0–121.4) 111.9 (104.7–119.1) .286
Laboratory ﬁnding
CA 19 to 9 (range) 174 (0–10,200) 43 (0–3700) 197 (5–10,200) .519
CEA (range) 3.0 (0.5–74.4) 3.0 (0.5–74.4) 3.0 (0.5–49.0) .266
NLR‡ (range) 2.0 (0.9–9.6) 2.1 (1.3–3.6) 2.5 (0.9–9.6) .207
Location, no (%) .700
Head 35 (54.7%) 7 (46.7%) 28 (57.1%)
Neck 7 (10.9%) 1 (6.7%) 6 (12.2%)
Body 19 (29.7%) 6 (40.0%) 13 (26.5%)
Tail 3 (4.7%) 1 (6.7%) 2 (4.1%)
Size (mm) 40 (16–88) 40 (28–50) 40 (16–88) .661
Involved vessel, n .254
Arteryx, only 12 (18.8%) 2 (13.3%) 10 (20.4%)
Veinjj, only 6 (9.4%) 0 (0%) 6 (12.2%)
Both vessels 46 (71.9%) 13 (86.7%) 33 (67.3%)
∗
ECOG PS= the eastern cooperative oncology group performance status.
† BMI=body mass index.
‡ NLR=neutrophil-to-lymphocyte ratio.
x Artery= celiac axis, superior mesenteric artery, common hepatic artery
jj Vein = superior mesenteric vein, portal vein.
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neutropenia was observed in 3 patients of the non-resected group,
among whom 2 experienced mortality due to sepsis, even after
schedule and dose modiﬁcation of FOLFIRINOX and use of
G-CSF.3.3. Surgical and long-term outcomes
Table 5 summarizes the clinical data for 15 patients who
underwent surgery for LAPC after neoadjuvant FOLFIRINOX.
The median time to resection was 6.7 months (3.2–14.3 months).
Among the 15 patients, 8 patients received pancreaticoduode-
nectomy and 7 received distal pancreatectomy. Eleven patients
achieved R0 resection following FOLFIRINOX therapy (73.3%),
9 patients had lymph nodes metastases, and 1 patient achieved
pathologic complete response. Twelve patients received adjuvant
chemotherapy (gemcitabine-based chemotherapy in 11 patients).
One patient, who displayed a systemic erythematous lupus
disorder, died of postoperative complication of acute mesenteric
artery thrombosis, despite heparinization after surgery.
During a median follow-up time of 9.4 months after resection
(1.8–35.5 months) and 23.1 months after diagnosis (15.0–46.1
months), 4 patients observed recurrences in 3.3, 5.1, 13.9, and
15.7 months, respectively, after resection. The cumulative
recurrence rate was 14.3% at 6 months and 28.5% at 18
months after resection. Among this cohort, 2 patients remained
alive 20.2 months and 35.5 months, respectively, after resection
(26.3 and 43.4 months after diagnosis, respectively). Ten patients
did not experience recurrence during the median follow-up time
of 20.3 months after resection (10.7 – 35.5 months) and 23.9
months after diagnosis (15.0–46.1 months).3The median OS for all enrolled patients was 17.0 months (1.9–
46.1 months). The 1-year survival rate for all patients was 70.3%
and the 2-year survival rate was 34.7%. The median OS of the
resected group was unable to be accurately calculated because >
50%of patients remain alive (>40months) but was clearly better
than that of the non-resected group (13.0 months) (Fig. 2).
3.4. Predictors associated with resectability
As shown in Table 6, the presence of dose reduction was
associated with the failure to convert to resectability in univariate
and multivariate logistic regression. The patients who received
reduced dose intensity in each cycle had lower probability of
subsequent resection compared with patients who received
standard dose of FOLFIRINOX (P= .024), although cRDIs did
not display statistically signiﬁcant differences between the groups
(P= .639). None of the other factors included in the regression
analyses were associated with resectability.4. Discussion
This study presents outcomes of a large series of patients with
LAPC who received neoadjuvant FOLFIRINOX chemotherapy
as a naïve treatment in a single institution. Our data show that
23.4% of patients with LAPC became resectable and surgical
candidates, and R0 resection was achieved in 73.3% of patients
after adequate FOLFIRINOX chemotherapy, in agreement with
a report from the western countries (25.9% and 78.4%,
respectively).[10] Furthermore, our data demonstrate that, for
obtaining resectability, it is advantageous to administer FOL-
FIRINOX without dose reduction, if tolerated by the patient.
FOLFIRINOX in LAPC, n=64
Resectable, n=15 (23.4%) Not-resectable, n=49 (76.6%)
Postoperative complication
Death, n=1
n=12 
Gemcitabine, n=11 
5-FU/Radiotherapy, n=1 
n=2 
Pathologic CR, n=1 
No recovery, n=1 
No recurrence, n=10 (71.4%)
Recurrence, n=4 (28.5%)
Death, n=2
Figure 1. Flowchart showing outcomes of patients treated with FOLFIRINOX for locally advanced pancreatic cancer. Of the 64 patients treated with FOLFIRINOX
for locally advanced pancreatic cancer, 15 patients had acquired resectability and underwent surgery. One patient, who had systemic erythematous lupus, died of
acute mesenteric artery thrombosis after surgery. Among 14 patients except 1 who died, 12 patients received adjuvant chemotherapy (gemcitabine-based
chemotherapy in 11 patients) and 2 patients did not receive adjuvant chemotherapy. One of the 2 patients who did not receive adjuvant chemotherapy was found to
have pathologic complete remission and the other had not yet recovered after surgery. Pancreatic cancer recurred in 4 patients of 14 patients and 2 patients died.
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gemcitabine-based neoadjuvant chemotherapy in patients with
LAPC, resection was performed in 27% of cases and the R0
resection ratio was only 23%.[12] In contrast, our data show that
around 1/4th of patients with LAPC can undergo resection, of
which about 75% are R0 resections, and this is in accordance
with a recent systematic review of FOLFIRINOX.[10] In
agreement with our results, patients with LAPC who underwent4surgery after neoadjuvant FOLFIRINOX can expect median OS
of >3 years, which is much longer than the median OS (∼24
months) of patients with resected pancreatic cancer.[10] There-
fore, the treatment strategy for patients with LAPC should be
changed to curative intent, rather than palliation, in the era of
FOLFIRINOX.
While methodologies and inﬂuential factors towards achieving
higher resection rate have not been well described, we found that
Table 2
Treatment: administration of FOLFIRINOX and chemoradiation.
Total patients, n=64 Resection, n=15 Non-resection, n=49 P
Cycles, no (range) 9 (1–20) 11 (2–16) 8 (1–20) .110
Duration (months) 6.0 (0.4–12.2) 6.4 (1.3–12.0) 5.5 (0.4–12.2) .196
Dose reduction, no 40 (62.5%) 5 (33.3%) 35 (71.4%) .013
cRDI
∗
(%) 70.0 (35.6–100.0) 71.8 (48.1–89.4) 69.6 (35.6–100.0) .228
Radiotherapy, no 19 (29.7%) 2 (13.3%) 17 (34.6%) .113
∗
cRDI= cumulative relative dose intensity.
Table 3
Efﬁcacy results after FOLFIRINOX.
Total patients, n=64 Resection, n=15 Non-resection, n=49 P
Response < .001
Complete response 1 (1.5%) 1 (6.7%) 0 (0%)
Partial response 13 (20.3%) 9 (60.0%) 4 (8.2%)
Stable disease 21 (32.8%) 5 (33.3%) 16 (32.7%)
Progressive disease 29 (45.3%) 0 (0%) 29 (59.2%)
Table 4
Grade 3 to 4 toxicities related to FOLFIRINOX treatment [n (%)].
Total patients n=64 Resection n=15 Non-resection n=49
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 P
Non-hematologic 23 (35.9%) 2 (13.3%) 21 (42.9%) .063
Nausea/vomiting 12 (18.8%) 0 (0%) 1 (6.7%) 0 (0%) 11 (22.4%) 0 (0%)
Diarrhea 8 (12.5%) 0 (0%) 0 (0%) 0 (0%) 8 (16.3%) 0 (0%)
Fatigue 7 (10.9%) 0 (0%) 0 (0%) 0 (0%) 7 (14.3%) 0 (0%)
Sensory neuropathy 3 (4.7%) 0 (0%) 1 (6.7%) 0 (0%) 2 (4.0%) 0 (0%)
Hematologic 33 (51.6%) 8 (53.3%) 25 (51.0%) .875
Neutropenia 11 (17.2%) 17 (26.6%) 2 (13.3%) 5 (33.3%) 9 (18.4%) 15 (30.6%)
Febrile neutropenia 7 (10.9%) 3 (4.7%) 2 (13.3%) 0 (0%) 5 (10.2%) 3 (6.1%)
Thrombocytope-nia 2 (3.1%) 1 (1.6%) 0 (0%) 0 (0%) 2 (13.3%) 2 (4.1%)
Anemia 9 (14.1%) 0 (0%) 2 (13.3%) 0 (0%) 7 (14.3%) 1 (2.0%)
Table 5
Summary of surgical and pathologic outcomes.
N=15
Preoperative radiotherapy 2 (13.3%)
Operation
Pancreaticoduodenectomy 8 (53.3%)
Distal pancreatectomy 7 (46.7%)
Postoperative pathologic stage
Stage 0 1 (6.7%)
Stage IIA 5 (33.3%)
Stage IIB 9 (60.0%)
Resection
R0 11 (73.3%)
R1 4 (26.7%)
Adjuvant treatment 12 (80.0%)
Gemcitabine 11
5FU/RT 1
Cumulative recurrence rate (6mo/18mo) 4 (28.5%) (2/2)
Death 3 (20.0%)
Tumor progression 2
Superior mesenteric arterial embolism 1
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5patients who maintain planned dose of FOLFIRINOX are more
likely to convert to displaying a resectable tumor than those who
do not, despite similar total administered dosage of FOLFIR-
INOX during treatments. In other words, interval modiﬁcation
may confer more resectability outcomes than dose modiﬁcation,
andwe suggest to 1st consider interval modiﬁcation, and whether
dose or schedule should be inevitably modiﬁed due to variable
reasons. Our results are supported by a recent study, which found
that increasing the number of full-dose neoadjuvant FOLFIR-
INOX treatments was signiﬁcantly associated with increased
survival.[13]
FOLFIRINOX displays adverse effects. Recently published
eastern data show much higher rates of grade 3 or 4 febrile
neutropenia in comparison with a report from the Western
countires (15.6% of our institution / 22.2% of Japanese patients
vs. 5% ofWestern patients).[10,14,15] In this study, 2 patients died
of neutropenic fever and accompanying complications after
FOLFIRINOX, despite the use of G-CSF and adequate dose and
interval modiﬁcation. This observation suggests that there may
be interracial differences, especially since there were no
treatment-related mortalities (0/355) in a recent systematic
[10]
Table 6
Predictable factors for resectability after FOLFIRINOX.
Univariate Analysis Multivariate Analysis
Factors HR (95% CI) P HR (95% CI) P
Age (>65 year) 0.252–2.653 .775 0.198–2.974 .702
CA 19–9 (>256.4) 0.135–1.738 .368 0.157–2.623 .537
Size (>4 cm) 0.272–3.726 .000 0.196–3.920 .862
Cycles (<6) 0.019–1.346 .089 0.021–1.832 .152
cRDI
∗
(<70%) 0.264–2.676 .000 0.267–4.587 .888
Dose reduction 0.058–0.691 .013 0.056–0.919 .038
∗
cRDI= cumulative relative dose intensity.
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how to maintain dose intensity while avoiding febrile neutrope-
nia in patients with LAPC who are treated with FOLFIRINOX,
especially in Asian populations. We do not observe febrile
neutropenia after the use of pegylated G-CSF. Based on our
experience and recent study showing preventive effect of
pegylated G-CSF against neutropenia during FOLFIRINOX,[16]
we would suggest that pegylated G-CSF can be an option for
keeping FOLFIRINOX dose intensity, although it requires
further investigation.
The role of radiotherapy in patients with LAPC remains a
controversial issue. Nineteen patients had SBRT with FOLFIR-
INOX and 2 patients achieved resectability (2/19, 10%). This
suggests that SBRT increases resectability when resectable status
is not achieved, even after adequate administration of FOLFIR-
INOX in patients with LAPC. Although SBRT has theoretical
advantages, such as short duration of radiation, delivery of more
ablative doses to the tumor, and minimization of interrupting
systemic chemotherapy, the role of SBRT in patients with LAPC
requires further clariﬁcation in the future.[17]
This study was limited to a single center retrospective analysis;
however, our data can be considered valuable because 64 patients
with LAPC who received FOLFIRINOX from a single center
represent one of the largest cohorts in the world, particularly in
Asian populations. Although we discovered that FOLFIRINOX
without dose modiﬁcation provides a higher rate of subsequent0
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Figure 2. Kaplan–Meier survival estimates of overall survival of groups with
resected (red line) and unresected (blue line) pancreatic cancer after
FOLFIRINOX treatment. The median overall survival (OS) for all enrolled
patients was 17.0 months (1.9–46.1 months). The median OS of the resected
group was unable to be accurately calculated because >50% of patients
remain alive (>40 months) but was clearly better than that of the non-resected
group (13.0 months). OS = overall survival.
6resectability in patients with LAPC, prospective studies should be
conducted to further clarify this ﬁnding.
In conclusion, FOLFIRINOX should be considered as an active
regimen in patients with LAPC, since this therapy provides an
acceptable resection rate and promising R0 resection rate. If
patients tolerate this treatment, the administration of FOLFIR-
INOX without dose reduction is associated with achieving
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